Objective: To establish the phenotypic spectrum of KIF5A mutations and to investigate whether KIF5A mutations cause axonal neuropathy associated with hereditary spastic paraplegia (HSP) or typical Charcot-Marie-Tooth disease type 2 (CMT2).
Patients. The diagnosis of HSP or CMT was based on clinical features, imaging, and neurophysiology. Acquired causes of spasticity and neuropathy were excluded. The majority of patients were assessed by M.M.R. and H.H. The vast majority of mutations have been identified mainly in the motor domain [1] [2] [3] [4] [5] [6] [7] [8] [9] ; therefore, this domain was screened in 2 series of patients. The first series included 186 unrelated patients with a clinical diagnosis of HSP with or without neuropathy (HSP series) and the second included 215 unrelated patients with axonal neuropathy consistent with CMT2 (CMT2 series). Patients in the HSP series were negative for mutations in SPAST, REEP1, NIPA1, ATL1, and BSCL2 and patients in the CMT2 series were usually negative for mutations in GJB1, MFN2, MPZ, GDAP1, BSCL2, TRPV4, NEFL, HSPB1, and HSPB8. A high-throughput targeted resequencing panel covering all coding exons of KIF5A was developed to screen an additional 66 unrelated patients with HSP or CMT2 with pyramidal signs. Most of these patients (58/66) were negative for ATL1 and SPAST mutations. One patient was analyzed by whole-exome sequencing (WES). As part of the diagnostic workup, patients carrying KIF5A mutations had neurologic examination and neurophysiologic assessment and one patient had a sural nerve biopsy. In patients with an identified KIF5A mutation, DNAs from affected family members were also tested for segregation where available.
Sanger sequencing. Genomic DNA was extracted from peripheral blood using Flexigene extraction kit and Autopure LS (Qiagen, Venlo, the Netherlands) extraction system. Coding regions and flanking introns of exons 1 to 12, which encode the motor domain of KIF5A (NM_004984), were amplified using Roche FastStart PCR Master Kit (Roche, Basel, Switzerland) according to manufacturers' instructions. Primers and conditions of PCR reactions are listed in table e-1 on the Neurology ® Web site at Neurology.org. Sequence reactions were performed using Big Dye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA), and KIF5A mutations (A) Chromatographs of the identified mutations and pedigree of the 6 patients in this study. The phenotypes illustrated in different colors refer to (1) classical Charcot-Marie-Tooth disease type 2 (CMT2): classical CMT2 phenotype without pyramidal sign; (2) CMT2 1 pyramidal signs: CMT2 is the main manifestation but there are associated pyramidal signs; (3) hereditary spastic paraplegia (HSP) 1 neuropathy: complex spastic paraplegia associated with peripheral neuropathy; (4) HSP, no neuropathy: spastic paraplegia without peripheral neuropathy. Parents of K-2 and K-3 were clinically unaffected at least until their sixth decades, though they were unavailable for genetic testing. Parents of K-5 died early due to non-neurologic diseases. (B) The amino acid residues where 2 novel missense mutations (R204W and D232N) occurred were highlighted on kinesin orthologues in various species. The alignment showed their strict conservation during evolution from zebrafish to human beings.
products were cleaned using BigDye Terminator removal plates (Applied Biosystems). PCR products were resolved on Applied Biosystems 3730XI Sequencer. The resulting sequences were aligned and analyzed with Sequencher (Gene Codes Corporation, Ann Arbor, MI) software. Whole-exome sequencing. Enrichment of coding exons and flanking intronic regions was performed using the SureSelect Human All Exon 50 Mb kit (Agilent) following the manufacturer's standard protocol. Enriched DNA was subjected to standard sample preparation for the Hiseq2000 instrument (Illumina). BWA and GATK software packages were used to align sequence reads to the NCBI hg19 reference and to call variant positions. 10, 11 All data were then annotated and imported into GEnomes Management Application (GEM.app) for data analysis.
12 Table 1 Clinical features of the patients with KIF5A mutations Variants were filtered with the same criteria applied in targeted resequencing.
Pathogenicity evaluation of novel mutations. p.Asp232Asn) are novel mutations. The novel mutations were not present in 221 exomes from healthy controls or the EVS and NMD databases. Furthermore, they were predicted to be probably damaging and not tolerated by Polyphen-2 and SIFT and each mutation changed a highly conserved amino acid residue (figure 1B). The above evidence supports the pathogenicity of these novel mutations.
Clinical and pathologic findings. Patients with KIF5A mutations presented with a variable phenotype and age at onset. The clinical features of the patients with KIF5A mutations are summarized in table 1. Among the 3 patients who had CMT2 as the predominant phenotype, only K-1 initially presented with a classical CMT2 phenotype, whereas the remaining 2 (K-2, K-3) had some involvement of the pyramidal tracts. The other 3 patients had spastic paraplegia as the main manifestation and 2 of them (K-4, K-6) also had peripheral neuropathy. Moreover, some patients had additional features: K-3, K-6, and other affected family members of K-6 had cognitive dysfunction and learning difficulties since their childhood; K-5 and her sister had marked cerebellar ataxia complicating the spasticity. R280C mutation was identified in 2 unrelated patients with different phenotypes: K-3 was of British origin and had the clinical diagnosis of CMT2 with a slight involvement of the corticospinal tract, whereas K-6, who had lived in Austria for several generations, presented with severe spastic paraplegia and mild peripheral neuropathy (figure 1A; K-3, K-6). Variable phenotypes in individuals within the same family were also observed. K-2, who had D232N mutation, presented with complex CMT2 associated with spasticity, whereas his brother had pure HSP ( figure 1A; K-2) .
Features demonstrating the simultaneous involvement of the peripheral nervous system and CNS in our patients are shown in figure 2 . A sural nerve biopsy from K-3 revealed markedly reduced numbers of large myelinated fibers, compatible with axonal degeneration ( figure 2, A-D) . Meanwhile, spasticity with hyperreflexia was observed on examination. K-2 had wasting of intrinsic foot muscles and pes cavus while the worn-out areas of the shoes indicated a long-standing spastic gait ( figure 2, G-H DISCUSSION This study reports the largest series of HSP and CMT2 patients screened for KIF5A mutations. The identification of 5 different mutations confirms that KIF5A is associated with both HSP and CMT2 phenotypes. We also report the first family with a KIF5A mutation who has associated cerebellar ataxia, broadening the phenotypic spectrum of KIF5A mutations.
The identified KIF5A mutations and their associated phenotypes are presented in figure 3 . HSP and CMT2 represent 2 different ends of the spectrum of KIF5A-related disorders: classical or complex CMT2 is relatively rare, while HSP with axonal neuropathy is the commonest phenotype associated with KIF5A mutations. However, a specific phenotype-genotype correlation for KIF5A mutations could not be defined as some mutations (R280C, R280H, and D232N) have been associated with more than one phenotype. The intrafamilial phenotypic variability within families with the D232N mutation provides the most straightforward evidence of the allelic relationship of HSP and CMT2.
KIF5A encodes the neuronal kinesis heavy chain (KHC) subunit of kinesin-1, a motor protein that plays a role in axonal transport. Kinesin-1 relies on the highly conserved motor domain of KHC to bind to the microtubules and converts the chemical energy of adenosine-59-triphosphate into mechanical energy required for intracellular trafficking. [13] [14] [15] [16] [17] [18] With both CMT2 and SPG10 phenotypes, the mutations are localized in the motor domain in the majority and clustering around the 2 switch regions (SWI and SWII in figure 3 ) that carry g-phosphate-sensing activity and are particularly important in the interaction with microtubules ( figure 3) . Half of the families in this study Table 2 Nerve conduction studies of the patients with KIF5A mutations have mutations at codon R280 and 25% (7/28) of all reported families with a KIF5A mutation have an amino acid substitution at this position. Although these families are from different regions and continents, it would be of interest to carry out a haplotype study to investigate a founder effect. The CpG dinucleotide of codon 280 had been proposed as a possible hot spot for KIF5A mutations. 17 Our findings support the critical role of this codon in the function of KIF5A.
A small number of SPG10-associated KIF5A mutations (K253N, N256S, R280C, and A361V) have been investigated using in vitro and Drosophila models. The results support a loss of endogenous kinesin-1 function due to a selective dominant-negative mechanism of action on the kinesin complexes, rather than a gain of toxicity. 15, 19 Only mutations located in the motor domain changed the kinesin gliding properties but the mutation in the neck (A361V) did not. This suggests that mutations outside of the motor domain may have a different disease mechanism.
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CMT2 and HSP have different target cells: the first primarily affects the peripheral nerves and the latter principally affects the corticospinal tract. Both the peripheral nerve axons and the long corticospinal tract rely heavily on axonal transport of appropriate cargoes to maintain normal axonal function. This may explain why KIF5A mutations can cause both HSP and CMT2 and the overlapping phenotypes. KIF5A is another example of a gene in which mutations can cause axonal neuropathy in association with pyramidal signs and is involved in axonal transport similar to BSCL2, REEP1, ATL1, SPAST, and NIPA1 genes. 13, 14, 18, 20 Likewise, CCT5, KIF1A, and DYNC1H1 are other genes encoding motor proteins that have an important role in axonal transport and their mutations have been identified in patients with complex syndromes involving both the peripheral nervous system and CNS. [21] [22] [23] [24] Thus axonal transport represents a potential common pathway in the pathogenesis of both axonal neuropathy and spastic paraplegia. 20 
Figure 3
Phenotypic spectrum of KIF5A mutations
Top: Genomic organization of the human KIF5A gene and its mutations. Most of the KIF5A mutations are localized in exon 8;10 and many are clustered within or around the switch I region (SWI) and the switch II region (SWII), which carry g-phosphate-sensing activity to convert adenosine-59-triphosphate into required energy. KIF5A mutations were labeled with the corresponding phenotypes: classical Charcot-Marie-Tooth disease type 2 (CMT2), CMT2 1 pyramidal signs, hereditary spastic paraplegia (HSP) 1 neuropathy, and HSP, no neuropathy (definitions of the phenotypes described in figure 1 ). The mutations identified in this study were flanked by the novel mutations in pink. The reference for each mutation is listed in table e-2. Bottom left: Venn diagram represents the overlap and distinct phenotypes of KIF5A mutations. The majority of these mutations presented with both spastic paraplegia and neuropathy.
Mutant motor proteins affecting axonal transport may lead to a neurodegenerative process. However, the mechanism by which mutations of the same gene can either selectively or simultaneously affect the upper motor neurons and the peripheral axons is still not well understood. Other genetic or environmental factors may influence the phenotype. Further studies are needed to understand the function of KIF5A and its roles in the peripheral nervous system and CNS. The reported frequency of KIF5A mutations may be an underestimate because of the expense of sequencing this large gene, which comprises 28 coding exons. The application of targeted resequencing for screening KIF5A provides a more comprehensive and costeffective method. In addition, next-generation targeted sequencing and WES are powerful tools for identifying mutations in patients with atypical complex symptoms. We have demonstrated that these approaches have effectively facilitated the detection of KIF5A mutations and helped broaden the phenotypic spectrum of this gene.
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